A global study establishes long-term risk of stroke. Findings shows one in five people who experience a minor stroke or TIA will have another stroke within 10 years.

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Current AF management guidelines have introduced the CARE treatment model to strengthen management ...

Every year, more than 795,000 American adults suffer a stroke, and one in four adults worldwide will suffer a stroke in their ...

Leqembi — sold through a partnership between Eisai Co. and Cambridge-based Biogen — is one of the first medications approved ...

Tenecteplase provides comparable safety and effectiveness outcomes for acute ischemic stroke as alteplase, new research ...

Recombinant human prourokinase is noninferior to alteplase in acute ischemic stroke, with symptomatic intracranial hemorrhage and major bleeding decreased.

An estimated 610,000 Americans are expected to experience their first stroke this year — but you don’t have to be one of them ...

According to the Centers for Disease Control and Prevention (CDC), more than 795,000 Americans experience a stroke every year, with approximately half a million people having one for the first time. A ...

Some headaches are minor and resolve with home treatment, but some are more severe ... a brain tumor a stroke an infection The headaches that result can occur in any location, including the ...

Tenecteplase (TNKase) is the first new clot-busting drug to be approved in nearly 30 years, with the U.S. Food and Drug Administration (FDA) giving it the thumbs-up earlier this m ...

“In treatment of acute ischemic stroke, there is the saying that ‘time is brain.’ The longer patients go without effective treatment, the more brain cells die, and the worse their outcome ...

Of course, this is only the first step – DDL-920 will need to undergo extensive human trials for safety and efficacy – however, it's a breakthrough in stroke treatment that could benefit millions.